154 related articles for article (PubMed ID: 27480274)
41. [Bone metastasis and RANKL].
Nakashima T
Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
[TBL] [Abstract][Full Text] [Related]
42. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
43. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
44. Biology of RANK, RANKL, and osteoprotegerin.
Boyce BF; Xing L
Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
[TBL] [Abstract][Full Text] [Related]
45. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
46. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
Beristain AG; Narala SR; Di Grappa MA; Khokha R
J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
[TBL] [Abstract][Full Text] [Related]
47. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
Zhang L; Teng Y; Fan Y; Wang Y; Li W; Shi J; Ma Y; Li C; Shi X; Qu X; Liu Y
Oncotarget; 2015 Sep; 6(26):22918-33. PubMed ID: 26087197
[TBL] [Abstract][Full Text] [Related]
48. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
[TBL] [Abstract][Full Text] [Related]
49. Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer.
Wang J; Liu Y; Wang L; Sun X; Wang Y
Oncotarget; 2016 Feb; 7(5):5564-75. PubMed ID: 26734994
[TBL] [Abstract][Full Text] [Related]
50. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Gómez-Aleza C; Nguyen B; Yoldi G; Ciscar M; Barranco A; Hernández-Jiménez E; Maetens M; Salgado R; Zafeiroglou M; Pellegrini P; Venet D; Garaud S; Trinidad EM; Benítez S; Vuylsteke P; Polastro L; Wildiers H; Simon P; Lindeman G; Larsimont D; Van den Eynden G; Velghe C; Rothé F; Willard-Gallo K; Michiels S; Muñoz P; Walzer T; Planelles L; Penninger J; Azim HA; Loi S; Piccart M; Sotiriou C; González-Suárez E
Nat Commun; 2020 Dec; 11(1):6335. PubMed ID: 33303745
[TBL] [Abstract][Full Text] [Related]
52. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Cell Cycle; 2017 Jun; 16(11):1022-1028. PubMed ID: 28387573
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
54. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
Sugatani T; Alvarez UM; Hruska KA
J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
[TBL] [Abstract][Full Text] [Related]
55. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
56. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
57. Autocrine PDGFR signaling promotes mammary cancer metastasis.
Jechlinger M; Sommer A; Moriggl R; Seither P; Kraut N; Capodiecci P; Donovan M; Cordon-Cardo C; Beug H; Grünert S
J Clin Invest; 2006 Jun; 116(6):1561-70. PubMed ID: 16741576
[TBL] [Abstract][Full Text] [Related]
58. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
[TBL] [Abstract][Full Text] [Related]
59. Modulation of tumor fatty acids, through overexpression or loss of thyroid hormone responsive protein spot 14 is associated with altered growth and metastasis.
Wellberg EA; Rudolph MC; Lewis AS; Padilla-Just N; Jedlicka P; Anderson SM
Breast Cancer Res; 2014 Dec; 16(6):481. PubMed ID: 25472762
[TBL] [Abstract][Full Text] [Related]
60. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
